Table ES-2Summary of the strength of evidence for KQ 2—venous thromboembolism

Number of Studies (Subjects)Domains Pertaining to SOESOE
Risk of Bias: Study Design/QualityConsistencyDirectnessPrecisionEffect Estimate (95% CI)
All-cause mortalityModerate SOE
2 (5988)RCT/GoodConsistentDirectSome imprecisionRR = 0.83 (0.59 to 1.18)
VTE-related mortalityLow SOE
2 (5988)RCT/GoodConsistentDirectImportant imprecisionRR = 0.56 (0.19 to 1.69)
Recurrent DVT/PEModerate SOE
2 (5988)RCT/GoodSome inconsistencyDirectSome imprecisionRR = 0.85 (0.54 to 1.33)
Discontinuation due to adverse effectsModerate SOE
2 (5988)RCT/GoodConsistentDirectSome imprecisionRR = 1.19 (0.93 to 1.51)
Major bleedingModerate SOE
2 (5988)RCT/GoodConsistentDirectSome imprecisionRR = 0.77 (0.49 to 1.20)

Abbreviations: CI = confidence interval; NA = not applicable; NR = not reported; RCT = randomized controlled trial; RR = risk ratio; SOE = strength of evidence

From: EXECUTIVE SUMMARY

Cover of Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism
Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism [Internet].
Adam SS, McDuffie JR, Ortel TL, et al.
Washington (DC): Department of Veterans Affairs (US); 2012 Apr.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.